A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 [fentanyl] for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 [fentanyl] for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2009

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Endo Pharmaceuticals
  • Most Recent Events

    • 12 May 2009 Actual End Date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2008 EMEA has issued a positive opinion, recommending approval of Abstral for the treatment of cancer pain, according to ProStarkan media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top